record antivirals sales, page-10

I also got in at almost exactly the same price, Rob, 1.865; I thought I missed the boat after the LANI announcement and was pleased to be able to buy in on the retrace. I agree that management has not always been the best, however the strength of the science of the products (Relenza/LANI) is so overwhelming it more than compensates for some management mistakes. GSK are not amateurs, so once they got behind Relenza success was a given. I just love the steady rises, not much day trade activity and the bots are OK, they can play around a bit, doesn't matter, we all know what's coming, a massive increase in Relenza sales figures and LANI licensing around the corner. I wish for IV Relenza too but I don't hold my hopes up too high.